MEDIPOST Co. Ltd (078160) - Total Assets
Based on the latest financial reports, MEDIPOST Co. Ltd (078160) holds total assets worth ₩374.57 Billion KRW (≈ $253.84 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of MEDIPOST Co. Ltd for net asset value and shareholders' equity analysis.
MEDIPOST Co. Ltd - Total Assets Trend (2011–2024)
This chart illustrates how MEDIPOST Co. Ltd's total assets have evolved over time, based on quarterly financial data.
MEDIPOST Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
MEDIPOST Co. Ltd's total assets of ₩374.57 Billion consist of 32.7% current assets and 67.3% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 7.9% |
| Accounts Receivable | ₩11.86 Billion | 2.9% |
| Inventory | ₩16.19 Billion | 3.9% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩2.61 Billion | 0.6% |
| Goodwill | ₩1.55 Billion | 0.4% |
Asset Composition Trend (2011–2024)
This chart illustrates how MEDIPOST Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is MEDIPOST Co. Ltd worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MEDIPOST Co. Ltd's current assets represent 32.7% of total assets in 2024, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 7.9% of total assets in 2024, down from 16.6% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 3.9% of total assets.
MEDIPOST Co. Ltd Competitors by Total Assets
Key competitors of MEDIPOST Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pluristem
TA:PSTI
|
Israel | ILA79.13 Million |
|
Hadasit Bio
TA:HDST
|
Israel | ILA14.67 Million |
|
Purple Biotech Ltd
TA:KTOV
|
Israel | ILA85.78 Million |
|
Peptron Inc
KQ:087010
|
Korea | ₩183.74 Billion |
|
Bioneer Corporation
KQ:064550
|
Korea | ₩376.52 Billion |
|
Macrogen Inc
KQ:038290
|
Korea | ₩341.60 Billion |
|
Cell Biotech Co. Ltd
KQ:049960
|
Korea | ₩134.57 Billion |
|
Panagene Inc
KQ:046210
|
Korea | ₩101.91 Billion |
MEDIPOST Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.96 | 2.60 | 1.39 |
| Quick Ratio | 2.40 | 2.33 | 1.24 |
| Cash Ratio | 0.00 | 0.40 | 0.00 |
| Working Capital | ₩58.63 Billion | ₩91.08 Billion | ₩24.46 Billion |
MEDIPOST Co. Ltd - Advanced Valuation Insights
This section examines the relationship between MEDIPOST Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.13 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -7.8% |
| Total Assets | ₩414.29 Billion |
| Market Capitalization | $290.79 Million USD |
Valuation Analysis
Below Book Valuation: The market values MEDIPOST Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: MEDIPOST Co. Ltd's assets decreased by 7.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for MEDIPOST Co. Ltd (2011–2024)
The table below shows the annual total assets of MEDIPOST Co. Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩414.29 Billion ≈ $280.76 Million |
-7.81% |
| 2023-12-31 | ₩449.39 Billion ≈ $304.55 Million |
+12.97% |
| 2022-12-31 | ₩397.79 Billion ≈ $269.58 Million |
+56.55% |
| 2021-12-31 | ₩254.09 Billion ≈ $172.20 Million |
+15.60% |
| 2020-12-31 | ₩219.81 Billion ≈ $148.96 Million |
+2.85% |
| 2019-12-31 | ₩213.72 Billion ≈ $144.83 Million |
+21.60% |
| 2018-12-31 | ₩175.75 Billion ≈ $119.11 Million |
+21.51% |
| 2017-12-31 | ₩144.65 Billion ≈ $98.02 Million |
-19.31% |
| 2016-12-31 | ₩179.26 Billion ≈ $121.49 Million |
-2.01% |
| 2015-12-31 | ₩182.93 Billion ≈ $123.97 Million |
-1.63% |
| 2014-12-31 | ₩185.97 Billion ≈ $126.03 Million |
+27.58% |
| 2013-12-31 | ₩145.77 Billion ≈ $98.79 Million |
+6.06% |
| 2012-12-31 | ₩137.44 Billion ≈ $93.14 Million |
+4.28% |
| 2011-12-31 | ₩131.79 Billion ≈ $89.32 Million |
-- |
About MEDIPOST Co. Ltd
MEDIPOST Co., Ltd. provides stem cell therapeutic solutions to meet the unmet medical needs in South Korea and internationally. It operates CELLTREE, an umbilical cord blood bank; and offers cord blood banking services to treat various incurable diseases. The company also markets CARTISTEM for the treatment of repetitive and/or traumatic cartilage degeneration, including degenerative osteoarthrit… Read more